Children's Medical Center Corporation

Other

Massachusetts Institute of Technology

Alseres Pharmaceuticals, Inc.

Boston Life Sciences, Inc.

Marsha A Moses

Dmitri G Wiederschain

Robert Samuel Langer

Richard M Thorn

Inmin Wu

Arthur J Sytkowski

Marc E Lanser

Dimitri G Wiederschain

Michael R Freeman

Debra Auguste

Li Yan

Peng Guo

Cecilia A Fernandez

Charles L Cooney

Mark Puder

Ramnath Sasisekharan

Daxing Liu

Robert S Langer

Matthew A Nugent

Mark A Lanser

Bo Zhang

Golnaz Morad

Jiang Yang

Roopali Roy

Jiang Jang

A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM˜1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.

Method for detecting or treating triple negative breast cancer

Provided herein are methods of determining whether an extracellular vesicle (EV) can cross an endothelial barrier (e.g., the blood brain barrier). In some embodiments, the EV originates from a cancer cell. In some embodiments, the cancer has a higher likelihood of metastasizing (to the brain) if the EV originating from a cancer cell is determined to be able to cross an endothelial barrier (e.g., the blood brain barrier). Thus, further provided herein are methods of determining whether a subject who has cancer is likely to develop metastatic cancer. In some embodiments, the subject is treated for the metastatic cancer accordingly.

Platform for assessment of the transcytosis of extracellular vesicles across endothelial barriers and uses thereof

The disclosure provides liposomes (e.g., cancer-targeting liposomes) with ligands (e.g., EGFR ligands and ICAM-1 ligands) conjugated to liposome surfaces. In some embodiments, the molecular ratio of different ligands complement the relative molecular density (i.e., ratio) of overexpressed protein on the surface of a cell targeted by the liposome (e.g., cancer cell).

Engineered liposomes as cancer-targeted therapeutics

The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase ('MMP') inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestinal operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

Method of treating fatty liver disease

Urinary Cyr61 protein levels are up regulated in patients that have cancers of epithelial origin, i.e. breast cancer and ovarian cancer. Accordingly, the present invention is directed to methods for prognostic evaluation, and diagnosis of cancers of epithelial origin. Further, the amount of Cyr61 protein detected in a urine sample correlates with disease status such that Cyr61 levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of Cyr61 in urine provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient.

Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin

The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homologous to amino acid residues 130-137 or 132-139 of human troponin subunit I.

Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1

Methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.

Non-invasive enzyme screen for tissue remodeling associated conditions

The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of fragments or homologs of troponin C, I or T subunits for the treatment of diseases or disorders involving abnormal angiogenesis.

Pharmaceutical compositions comprising fragments and homologs of troponin subunits

The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1, or a fragment thereof, which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the fragment has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 &#x3bc;g/ml-20 &#x3bc;g/ml, more preferably 75% inhibition, most preferably 95% inhibition.

Antiangiogenic peptides

Non-invasive enzyme screen for tissue remodelling-associated conditions

The present invention relates to methods of inhibiting angiogenesis associated with a disease or disorder with peptides homologous to amino acid residues 130&#x2013;137 or 132&#x2013;139 of human troponin subunit I.

Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit I

The present invention relates to non-invasive methods for facilitating the diagnosis of a subject as having cancer. The described methods involve detecting the presence of a matrix metalloproteinase in urine samples obtained from a patient and correlating the presence or absence of the matrix metalloproteinase with the presence or absence of cancer. Methods for monitoring the prognosis of a patient by detection of matrix metalloproteinase are also provided.

Non-invasive enzyme screen for cancer

The present invention provides an antiangiogenic polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or a portion thereof which is effective to inhibit endothelial cell proliferation as determined by the capillary EC proliferation assay. Preferably, the portion has at least 50% inhibition of bFGF-stimulated EC proliferation at 5 Tg/ml, more preferably 75% inhibition, most preferably 95% inhibition.

Antiangiogenic peptides and compositions thereof

Pharmaceutical compositions and methods of treatment of diseases or disorders involving angiogenesis with therapeutically effective amounts of troponin C, I, or T, subunits, fragments, or analogs thereof.

Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis

The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of recombinant troponin C, I or T subunits for the treatment of diseases or disorders involving abnormal angiogenesis.

Growing community of inventors

Brookline, MA, United States of America

Marsha A Moses